



Lynparza[®] (olaparib) – New indication

- On December 19, 2018, [AstraZeneca](#) and [Merck announced](#) the FDA approval of [Lynparza \(olaparib\)](#) tablets for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic *BRCA*-mutated (*gBRCAm* or *sBRCAm*) advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy.
 - Patients with *gBRCAm* advanced epithelial ovarian, fallopian tube or primary peritoneal cancer should be selected for therapy based on an FDA-approved companion diagnostic for Lynparza.
 - Lynparza is also approved for the maintenance treatment of recurrent ovarian cancer, advanced *gBRCA*-mutated ovarian cancer after 3 or more lines of chemotherapy, and for germline *BRCA*-mutated HER2-negative metastatic breast cancer.
- Ovarian cancer is a leading cause of cancer death in women worldwide, with a five-year survival rate of 19%. In 2018, there were over 295,000 new cases diagnosed and around 185,000 deaths.
- The new indication for Lynparza was based on data from a placebo-controlled study of 391 patients with *BRCA*-mutated advanced ovarian, fallopian tube, or primary peritoneal cancer following first-line platinum-based chemotherapy. The major efficacy outcome was progression-free survival (PFS).
 - The Lynparza group demonstrated a statistically significant improvement in PFS vs. placebo (HR: 0.30, 95% CI: 0.23 – 0.41; $p < 0.0001$).
 - The median PFS was 13.8 months with placebo and not reached with Lynparza.
 - At the time of the analysis of PFS, overall survival data were not mature (21% of patients had died).
- The recommended initial dose of Lynparza for all indications is 300 mg taken orally twice daily with or without food.
 - Treatment should be continued until disease progression, unacceptable toxicity, or completion of 2 years of treatment.
 - Patients with a complete response (no radiological evidence of disease) at 2 years should stop treatment. Patients with evidence of disease at 2 years, who in the opinion of the treating healthcare provider can derive further benefit from continuous treatment, can be treated beyond 2 years.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.